{
  "version": "https://jsonfeed.org/version/1.1",
  "title": "FDA press releases",
  "home_page_url": "https://www.fda.gov/news-events/fda-newsroom/press-announcements",
  "description": "Events collected by UnlimitedPipe 0.10.62",
  "_unlimitedpipe": {
    "schema": "unlimitedpipe.event/1",
    "generator": "UnlimitedPipe 0.10.62"
  },
  "items": [
    {
      "id": "f400cf36028cf5e12873",
      "title": "FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide",
      "content_text": "FDA today announced the Global Reliance Disclosure Program (GRDP), a landmark initiative that will fundamentally transform how the FDA's regulatory drug and biologic approval decisions are leveraged by health authorities around the world.",
      "date_published": "2026-11-17T20:32:16Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "f400cf36028cf5e12873",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-11-17T22:50:48Z",
          "data": {
            "change": "added",
            "label": "FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide",
            "item_type": "entry",
            "summary": "added: FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide",
            "after": {
              "title": "FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide",
              "author": "FDA",
              "published_at": "2026-11-17T20:32:16Z",
              "updated_at": "2026-11-17T20:32:16Z",
              "summary": "FDA today announced the Global Reliance Disclosure Program (GRDP), a landmark initiative that will fundamentally transform how the FDA's regulatory drug and biologic approval decisions are leveraged by health authorities around the world.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 74,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide"
    },
    {
      "id": "21b844c97cda7d04edb0",
      "title": "FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer",
      "content_text": "FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.",
      "date_published": "2026-11-17T19:15:22Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "21b844c97cda7d04edb0",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-11-17T19:58:38Z",
          "data": {
            "change": "added",
            "label": "FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer",
            "item_type": "entry",
            "summary": "added: FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer",
            "after": {
              "title": "FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer",
              "author": "FDA",
              "published_at": "2026-11-17T19:15:22Z",
              "updated_at": "2026-11-17T19:15:22Z",
              "summary": "FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 149,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer"
    },
    {
      "id": "ccb5f3bd8e918312100b",
      "title": "FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk",
      "content_text": "FDA today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.",
      "date_published": "2026-11-09T22:15:46Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "ccb5f3bd8e918312100b",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-11-10T06:42:52Z",
          "data": {
            "change": "added",
            "label": "FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk",
            "item_type": "entry",
            "summary": "added: FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk",
            "after": {
              "title": "FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk",
              "author": "FDA",
              "published_at": "2026-11-09T22:15:46Z",
              "updated_at": "2026-11-09T22:15:46Z",
              "summary": "FDA today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 48,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk"
    },
    {
      "id": "1da4ed21ef2c58db3b1e",
      "title": "FDA Launches Expedited IND Pilot, Begins Accepting Applications",
      "content_text": "The U.S. Food and Drug Administration today announced the final design of the Expedited Investigational New Drug (IND) Pilot.",
      "date_published": "2026-09-15T13:53:31Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "1da4ed21ef2c58db3b1e",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-launches-expedited-ind-pilot-begins-accepting-applications",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-11-10T05:37:10Z",
          "data": {
            "change": "added",
            "label": "FDA Launches Expedited IND Pilot, Begins Accepting Applications",
            "item_type": "entry",
            "summary": "added: FDA Launches Expedited IND Pilot, Begins Accepting Applications",
            "after": {
              "title": "FDA Launches Expedited IND Pilot, Begins Accepting Applications",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-launches-expedited-ind-pilot-begins-accepting-applications",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-launches-expedited-ind-pilot-begins-accepting-applications",
              "author": "FDA",
              "published_at": "2026-09-15T13:53:31Z",
              "updated_at": "2026-09-15T13:53:31Z",
              "summary": "The U.S. Food and Drug Administration today announced the final design of the Expedited Investigational New Drug (IND) Pilot.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 49,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-launches-expedited-ind-pilot-begins-accepting-applications"
    },
    {
      "id": "d2b3d8e893100c0b06fe",
      "title": "FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma",
      "content_text": "The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherap",
      "date_published": "2026-11-05T22:30:38Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "d2b3d8e893100c0b06fe",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-11-06T05:48:55Z",
          "data": {
            "change": "added",
            "label": "FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma",
            "item_type": "entry",
            "summary": "added: FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma",
            "after": {
              "title": "FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma",
              "author": "FDA",
              "published_at": "2026-11-05T22:30:38Z",
              "updated_at": "2026-11-05T22:30:38Z",
              "summary": "The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherap",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 62,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma"
    },
    {
      "id": "6b0ab710c0f28efb9848",
      "title": "FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition Products",
      "content_text": "The U.S. Food and Drug Administration today announced it is taking action, consistent with the Trump administration’s commitment to protecting vulnerable patients and maintaining access to critical medical products, to help address a potential supply gap of neonatal starter parenteral nutrition (PN)",
      "date_published": "2026-09-04T20:18:49Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "6b0ab710c0f28efb9848",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-takes-steps-maintain-newborn-access-life-saving-starter-nutrition-products",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-11-06T04:51:10Z",
          "data": {
            "change": "added",
            "label": "FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition Products",
            "item_type": "entry",
            "summary": "added: FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition Products",
            "after": {
              "title": "FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition Products",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-takes-steps-maintain-newborn-access-life-saving-starter-nutrition-products",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-takes-steps-maintain-newborn-access-life-saving-starter-nutrition-products",
              "author": "FDA",
              "published_at": "2026-09-04T20:18:49Z",
              "updated_at": "2026-09-04T20:18:49Z",
              "summary": "The U.S. Food and Drug Administration today announced it is taking action, consistent with the Trump administration’s commitment to protecting vulnerable patients and maintaining access to critical medical products, to help address a potential supply gap of neonatal starter parenteral nutrition (PN)",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 61,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-takes-steps-maintain-newborn-access-life-saving-starter-nutrition-products"
    },
    {
      "id": "700b65cf6a99ac297f11",
      "title": "FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality",
      "content_text": "The U.S. Food and Drug Administration today issued final guidance for manufacturers of cellular and gene therapy (CGT) products to implement a comprehensive, science- and risk-based plan for making sure their products meet potency standards.",
      "date_published": "2026-11-02T13:56:06Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "700b65cf6a99ac297f11",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-provides-clarity-support-cell-and-gene-therapy-development-and-quality",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-11-05T09:57:48Z",
          "data": {
            "change": "added",
            "label": "FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality",
            "item_type": "entry",
            "summary": "added: FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality",
            "after": {
              "title": "FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-provides-clarity-support-cell-and-gene-therapy-development-and-quality",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-provides-clarity-support-cell-and-gene-therapy-development-and-quality",
              "author": "FDA",
              "published_at": "2026-11-02T13:56:06Z",
              "updated_at": "2026-11-02T13:56:06Z",
              "summary": "The U.S. Food and Drug Administration today issued final guidance for manufacturers of cellular and gene therapy (CGT) products to implement a comprehensive, science- and risk-based plan for making sure their products meet potency standards.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 99,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-provides-clarity-support-cell-and-gene-therapy-development-and-quality"
    },
    {
      "id": "2d010ab2f631c2a8efc0",
      "title": "FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis",
      "content_text": "The U.S. Food and Drug Administration today granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP).",
      "date_published": "2026-10-30T20:32:08Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "2d010ab2f631c2a8efc0",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-plasmid-dna-based-immunotherapy-adults-recurrent-respiratory-papillomatosis",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-11-05T09:57:48Z",
          "data": {
            "change": "added",
            "label": "FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis",
            "item_type": "entry",
            "summary": "added: FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis",
            "after": {
              "title": "FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-plasmid-dna-based-immunotherapy-adults-recurrent-respiratory-papillomatosis",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-plasmid-dna-based-immunotherapy-adults-recurrent-respiratory-papillomatosis",
              "author": "FDA",
              "published_at": "2026-10-30T20:32:08Z",
              "updated_at": "2026-10-30T20:32:08Z",
              "summary": "The U.S. Food and Drug Administration today granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP).",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 99,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-plasmid-dna-based-immunotherapy-adults-recurrent-respiratory-papillomatosis"
    },
    {
      "id": "37355ddec449b227384b",
      "title": "FDA Launches New Program to Advance Neuroscience Medical Product Development",
      "content_text": "FDA announces the launch of the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency program aligned with the Trump Administration’s efforts to accelerate medical innovation and deliver breakthrough treatments.",
      "date_published": "2026-10-22T16:58:19Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "37355ddec449b227384b",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-launches-new-program-advance-neuroscience-medical-product-development",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-11-05T09:57:48Z",
          "data": {
            "change": "added",
            "label": "FDA Launches New Program to Advance Neuroscience Medical Product Development",
            "item_type": "entry",
            "summary": "added: FDA Launches New Program to Advance Neuroscience Medical Product Development",
            "after": {
              "title": "FDA Launches New Program to Advance Neuroscience Medical Product Development",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-launches-new-program-advance-neuroscience-medical-product-development",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-launches-new-program-advance-neuroscience-medical-product-development",
              "author": "FDA",
              "published_at": "2026-10-22T16:58:19Z",
              "updated_at": "2026-10-22T16:58:19Z",
              "summary": "FDA announces the launch of the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency program aligned with the Trump Administration’s efforts to accelerate medical innovation and deliver breakthrough treatments.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 99,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-launches-new-program-advance-neuroscience-medical-product-development"
    },
    {
      "id": "3537e6a8ec61dbd8edee",
      "title": "FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment",
      "content_text": "FDA today approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis.",
      "date_published": "2026-10-20T19:40:38Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "3537e6a8ec61dbd8edee",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-chronic-hepatitis-b-treatment",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-11-05T09:57:48Z",
          "data": {
            "change": "added",
            "label": "FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment",
            "item_type": "entry",
            "summary": "added: FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment",
            "after": {
              "title": "FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-chronic-hepatitis-b-treatment",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-chronic-hepatitis-b-treatment",
              "author": "FDA",
              "published_at": "2026-10-20T19:40:38Z",
              "updated_at": "2026-10-20T19:40:38Z",
              "summary": "FDA today approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 99,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-chronic-hepatitis-b-treatment"
    },
    {
      "id": "c401c8b6324d86aff1fd",
      "title": "FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women",
      "content_text": "Today, the U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week.",
      "date_published": "2026-10-20T15:57:36Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "c401c8b6324d86aff1fd",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-approves-once-weekly-generic-hormone-therapy-patch-women",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-11-05T09:57:48Z",
          "data": {
            "change": "added",
            "label": "FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women",
            "item_type": "entry",
            "summary": "added: FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women",
            "after": {
              "title": "FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-once-weekly-generic-hormone-therapy-patch-women",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-approves-once-weekly-generic-hormone-therapy-patch-women",
              "author": "FDA",
              "published_at": "2026-10-20T15:57:36Z",
              "updated_at": "2026-10-20T15:57:36Z",
              "summary": "Today, the U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 99,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-once-weekly-generic-hormone-therapy-patch-women"
    },
    {
      "id": "b1a2f25d7a29db048295",
      "title": "FDA Issues Final Guidance on Prescription Drug Apps and Software",
      "content_text": "The U.S. Food and Drug Administration today released final guidance establishing a clear framework for how drug companies can develop, distribute, and label apps used alongside their prescription medicines.",
      "date_published": "2026-10-20T13:03:14Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "b1a2f25d7a29db048295",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-issues-final-guidance-prescription-drug-apps-and-software",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-11-05T09:57:48Z",
          "data": {
            "change": "added",
            "label": "FDA Issues Final Guidance on Prescription Drug Apps and Software",
            "item_type": "entry",
            "summary": "added: FDA Issues Final Guidance on Prescription Drug Apps and Software",
            "after": {
              "title": "FDA Issues Final Guidance on Prescription Drug Apps and Software",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-issues-final-guidance-prescription-drug-apps-and-software",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-issues-final-guidance-prescription-drug-apps-and-software",
              "author": "FDA",
              "published_at": "2026-10-20T13:03:14Z",
              "updated_at": "2026-10-20T13:03:14Z",
              "summary": "The U.S. Food and Drug Administration today released final guidance establishing a clear framework for how drug companies can develop, distribute, and label apps used alongside their prescription medicines.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 99,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-issues-final-guidance-prescription-drug-apps-and-software"
    },
    {
      "id": "e1875b9da3e0c616dee6",
      "title": "FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery",
      "content_text": "The U.S. Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common treatments that can have a lasting impact on their daily life.",
      "date_published": "2026-10-19T16:19:38Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "e1875b9da3e0c616dee6",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-approves-immunotherapy-may-allow-certain-patients-rectal-cancer-avoid-chemotherapy-radiation-and",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-11-05T09:57:48Z",
          "data": {
            "change": "added",
            "label": "FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery",
            "item_type": "entry",
            "summary": "added: FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery",
            "after": {
              "title": "FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-immunotherapy-may-allow-certain-patients-rectal-cancer-avoid-chemotherapy-radiation-and",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-approves-immunotherapy-may-allow-certain-patients-rectal-cancer-avoid-chemotherapy-radiation-and",
              "author": "FDA",
              "published_at": "2026-10-19T16:19:38Z",
              "updated_at": "2026-10-19T16:19:38Z",
              "summary": "The U.S. Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common treatments that can have a lasting impact on their daily life.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 99,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-immunotherapy-may-allow-certain-patients-rectal-cancer-avoid-chemotherapy-radiation-and"
    },
    {
      "id": "150d6d03920e594d234e",
      "title": "FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development",
      "content_text": "The U.S. Food and Drug Administration, a division within the U.S. Department of Health and Human Services (HHS), today announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases.",
      "date_published": "2026-10-14T15:50:52Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "150d6d03920e594d234e",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-11-05T09:57:48Z",
          "data": {
            "change": "added",
            "label": "FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development",
            "item_type": "entry",
            "summary": "added: FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development",
            "after": {
              "title": "FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease",
              "author": "FDA",
              "published_at": "2026-10-14T15:50:52Z",
              "updated_at": "2026-10-14T15:50:52Z",
              "summary": "The U.S. Food and Drug Administration, a division within the U.S. Department of Health and Human Services (HHS), today announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 99,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease"
    },
    {
      "id": "7f9cc3c94d1d0a86bf82",
      "title": "FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer",
      "content_text": "FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer",
      "date_published": "2026-10-14T15:14:51Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "7f9cc3c94d1d0a86bf82",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-certain-people-bcg-unresponsive-bladder-cancer",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-11-05T09:57:48Z",
          "data": {
            "change": "added",
            "label": "FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer",
            "item_type": "entry",
            "summary": "added: FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer",
            "after": {
              "title": "FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-certain-people-bcg-unresponsive-bladder-cancer",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-certain-people-bcg-unresponsive-bladder-cancer",
              "author": "FDA",
              "published_at": "2026-10-14T15:14:51Z",
              "updated_at": "2026-10-14T15:14:51Z",
              "summary": "FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 99,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-certain-people-bcg-unresponsive-bladder-cancer"
    },
    {
      "id": "19c220a9d4f9549c8c5d",
      "title": "FDA Seeks Public Input to Support Ibogaine Research",
      "content_text": "The U.S. Food and Drug Administration today announced a request for information (RFI) describing approaches the agency is considering for the design of early-phase clinical trials of ibogaine drug products and seeking public input on those approaches.",
      "date_published": "2026-10-05T13:02:06Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "19c220a9d4f9549c8c5d",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-support-ibogaine-research",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-10-05T16:39:06Z",
          "data": {
            "change": "added",
            "label": "FDA Seeks Public Input to Support Ibogaine Research",
            "item_type": "entry",
            "summary": "added: FDA Seeks Public Input to Support Ibogaine Research",
            "after": {
              "title": "FDA Seeks Public Input to Support Ibogaine Research",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-support-ibogaine-research",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-support-ibogaine-research",
              "author": "FDA",
              "published_at": "2026-10-05T13:02:06Z",
              "updated_at": "2026-10-05T13:02:06Z",
              "summary": "The U.S. Food and Drug Administration today announced a request for information (RFI) describing approaches the agency is considering for the design of early-phase clinical trials of ibogaine drug products and seeking public input on those approaches.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 126,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-support-ibogaine-research"
    },
    {
      "id": "b0ed8407f4f141e6cb4d",
      "title": "FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia",
      "content_text": "The U.S. Food and Drug Administration today issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr) as the first-ever treatment for adults and children 8 years of age and older with glycogen storage disease type Ia (GSDIa)",
      "date_published": "2026-08-19T21:33:10Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "b0ed8407f4f141e6cb4d",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-patients-aged-8-years-and-older-glycogen-storage-disease-type-ia",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-10-05T15:39:37Z",
          "data": {
            "change": "added",
            "label": "FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia",
            "item_type": "entry",
            "summary": "added: FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia",
            "after": {
              "title": "FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-patients-aged-8-years-and-older-glycogen-storage-disease-type-ia",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-patients-aged-8-years-and-older-glycogen-storage-disease-type-ia",
              "author": "FDA",
              "published_at": "2026-08-19T21:33:10Z",
              "updated_at": "2026-08-19T21:33:10Z",
              "summary": "The U.S. Food and Drug Administration today issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr) as the first-ever treatment for adults and children 8 years of age and older with glycogen storage disease type Ia (GSDIa)",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 83,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.62"
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.62",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-patients-aged-8-years-and-older-glycogen-storage-disease-type-ia"
    },
    {
      "id": "6101514d9e0c5a5435e4",
      "title": "FDA Approves First Heart Valve Designed to Grow with Children",
      "content_text": "The U.S. Food and Drug Administration today approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease.",
      "date_published": "2026-10-01T19:02:08Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "6101514d9e0c5a5435e4",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-heart-valve-designed-grow-children",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-10-01T19:46:20Z",
          "data": {
            "change": "added",
            "label": "FDA Approves First Heart Valve Designed to Grow with Children",
            "item_type": "entry",
            "summary": "added: FDA Approves First Heart Valve Designed to Grow with Children",
            "after": {
              "title": "FDA Approves First Heart Valve Designed to Grow with Children",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-heart-valve-designed-grow-children",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-heart-valve-designed-grow-children",
              "author": "FDA",
              "published_at": "2026-10-01T19:02:08Z",
              "updated_at": "2026-10-01T19:02:08Z",
              "summary": "The U.S. Food and Drug Administration today approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 87,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.32"
            },
            {
              "step": "dedupe",
              "version": "0.10.32",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.32",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.32",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-heart-valve-designed-grow-children"
    },
    {
      "id": "5ecf21fa709c48d6cf0a",
      "title": "FDA Launches Nationwide Effort to Expand Scientific Expertise and Consumer Voices to Advisory Committees",
      "content_text": "The U.S. Food and Drug Administration today announced a broad, nationwide recruitment effort to expand the range of qualified voices and perspectives on its advisory committees— the independent bodies that inform some of the most consequential decisions in American public health.",
      "date_published": "2026-09-30T13:26:33Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "5ecf21fa709c48d6cf0a",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-launches-nationwide-effort-expand-scientific-expertise-and-consumer-voices-advisory-committees",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-30T17:48:58Z",
          "data": {
            "change": "added",
            "label": "FDA Launches Nationwide Effort to Expand Scientific Expertise and Consumer Voices to Advisory Committees",
            "item_type": "entry",
            "summary": "added: FDA Launches Nationwide Effort to Expand Scientific Expertise and Consumer Voices to Advisory Committees",
            "after": {
              "title": "FDA Launches Nationwide Effort to Expand Scientific Expertise and Consumer Voices to Advisory Committees",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-launches-nationwide-effort-expand-scientific-expertise-and-consumer-voices-advisory-committees",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-launches-nationwide-effort-expand-scientific-expertise-and-consumer-voices-advisory-committees",
              "author": "FDA",
              "published_at": "2026-09-30T13:26:33Z",
              "updated_at": "2026-09-30T13:26:33Z",
              "summary": "The U.S. Food and Drug Administration today announced a broad, nationwide recruitment effort to expand the range of qualified voices and perspectives on its advisory committees— the independent bodies that inform some of the most consequential decisions in American public health.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 55,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.32"
            },
            {
              "step": "dedupe",
              "version": "0.10.32",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.32",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.32",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-launches-nationwide-effort-expand-scientific-expertise-and-consumer-voices-advisory-committees"
    },
    {
      "id": "41631d700bad63976396",
      "title": "FDA Seeks Public Feedback to Inform Regulatory Approach for Generative AI-Enabled Medical Devices",
      "content_text": "The U.S. Food and Drug Administration today issued a discussion paper on considerations for the regulation of generative artificial intelligence (GenAI)-enabled medical devices, seeking feedback from interested parties on risk assessment, premarket evaluation, postmarket monitoring, and other topics",
      "date_published": "2026-08-18T14:10:03Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "41631d700bad63976396",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-seeks-public-feedback-inform-regulatory-approach-generative-ai-enabled-medical-devices",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-30T16:51:37Z",
          "data": {
            "change": "added",
            "label": "FDA Seeks Public Feedback to Inform Regulatory Approach for Generative AI-Enabled Medical Devices",
            "item_type": "entry",
            "summary": "added: FDA Seeks Public Feedback to Inform Regulatory Approach for Generative AI-Enabled Medical Devices",
            "after": {
              "title": "FDA Seeks Public Feedback to Inform Regulatory Approach for Generative AI-Enabled Medical Devices",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-seeks-public-feedback-inform-regulatory-approach-generative-ai-enabled-medical-devices",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-seeks-public-feedback-inform-regulatory-approach-generative-ai-enabled-medical-devices",
              "author": "FDA",
              "published_at": "2026-08-18T14:10:03Z",
              "updated_at": "2026-08-18T14:10:03Z",
              "summary": "The U.S. Food and Drug Administration today issued a discussion paper on considerations for the regulation of generative artificial intelligence (GenAI)-enabled medical devices, seeking feedback from interested parties on risk assessment, premarket evaluation, postmarket monitoring, and other topics",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 53,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.32"
            },
            {
              "step": "dedupe",
              "version": "0.10.32",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.32",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.32",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-seeks-public-feedback-inform-regulatory-approach-generative-ai-enabled-medical-devices"
    },
    {
      "id": "9ab28dfd48dbf2e949dc",
      "title": "FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme",
      "content_text": "The U.S. Attorney’s Office for the Middle District of Florida and the Criminal Division of the U.S. Department of Justice today announced federal charges against Swapnadip Roy, 33, and Vicky Ramancha, 37, both Indian nationals.",
      "date_published": "2026-09-29T21:01:07Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "9ab28dfd48dbf2e949dc",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-investigation-leads-charges-against-two-indian-nationals-involved-transnational-counterfeit-drug",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-29T23:44:22Z",
          "data": {
            "change": "added",
            "label": "FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme",
            "item_type": "entry",
            "summary": "added: FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme",
            "after": {
              "title": "FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-investigation-leads-charges-against-two-indian-nationals-involved-transnational-counterfeit-drug",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-investigation-leads-charges-against-two-indian-nationals-involved-transnational-counterfeit-drug",
              "author": "FDA",
              "published_at": "2026-09-29T21:01:07Z",
              "updated_at": "2026-09-29T21:01:07Z",
              "summary": "The U.S. Attorney’s Office for the Middle District of Florida and the Criminal Division of the U.S. Department of Justice today announced federal charges against Swapnadip Roy, 33, and Vicky Ramancha, 37, both Indian nationals.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 48,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.32"
            },
            {
              "step": "dedupe",
              "version": "0.10.32",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.32",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.32",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-investigation-leads-charges-against-two-indian-nationals-involved-transnational-counterfeit-drug"
    },
    {
      "id": "385ab3805bb9218964d8",
      "title": "FDA Approves First Treatment for MCT8 Deficiency",
      "content_text": "The U.S. Food and Drug Administration today approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patient",
      "date_published": "2026-09-28T21:43:18Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "385ab3805bb9218964d8",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-mct8-deficiency",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-29T09:25:43Z",
          "data": {
            "change": "added",
            "label": "FDA Approves First Treatment for MCT8 Deficiency",
            "item_type": "entry",
            "summary": "added: FDA Approves First Treatment for MCT8 Deficiency",
            "after": {
              "title": "FDA Approves First Treatment for MCT8 Deficiency",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-mct8-deficiency",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-mct8-deficiency",
              "author": "FDA",
              "published_at": "2026-09-28T21:43:18Z",
              "updated_at": "2026-09-28T21:43:18Z",
              "summary": "The U.S. Food and Drug Administration today approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patient",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 120,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.32"
            },
            {
              "step": "dedupe",
              "version": "0.10.32",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.32",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.32",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-mct8-deficiency"
    },
    {
      "id": "0e002a5f7ee86f6ed5fe",
      "title": "FDA intends to evaluate changes to the PMTA regulatory framework",
      "content_text": "FDA is carefully reviewing its experience implementing the Premarket Tobacco Product Application (PMTA) rule, as well as recent judicial developments, including a federal lawsuit filed in the U.S. District Court for the Northern District of Texas challenging the current regulatory framework.",
      "date_published": "2026-09-28T21:00:01Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "0e002a5f7ee86f6ed5fe",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-intends-evaluate-changes-pmta-regulatory-framework",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-29T09:25:43Z",
          "data": {
            "change": "added",
            "label": "FDA intends to evaluate changes to the PMTA regulatory framework",
            "item_type": "entry",
            "summary": "added: FDA intends to evaluate changes to the PMTA regulatory framework",
            "after": {
              "title": "FDA intends to evaluate changes to the PMTA regulatory framework",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-intends-evaluate-changes-pmta-regulatory-framework",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-intends-evaluate-changes-pmta-regulatory-framework",
              "author": "FDA",
              "published_at": "2026-09-28T21:00:01Z",
              "updated_at": "2026-09-28T21:00:01Z",
              "summary": "FDA is carefully reviewing its experience implementing the Premarket Tobacco Product Application (PMTA) rule, as well as recent judicial developments, including a federal lawsuit filed in the U.S. District Court for the Northern District of Texas challenging the current regulatory framework.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 120,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.32"
            },
            {
              "step": "dedupe",
              "version": "0.10.32",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.32",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.32",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-intends-evaluate-changes-pmta-regulatory-framework"
    },
    {
      "id": "1afdd1e92eab6afec938",
      "title": "FDA Issues Emergency Use Authorization for Drug to Prevent New World Screwworm in Multiple Species, Including Sheep, Cattle, Goats, and Swine",
      "content_text": "FDA today issued an Emergency Use Authorization (EUA) for CLiK Extra (dicyclanil topical suspension) wound spray for application on or around wounds for the prevention of New World screwworm (NWS) infestations (myiasis).",
      "date_published": "2026-08-07T13:00:09Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "1afdd1e92eab6afec938",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drug-prevent-new-world-screwworm-multiple-species-including",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-29T08:28:52Z",
          "data": {
            "change": "added",
            "label": "FDA Issues Emergency Use Authorization for Drug to Prevent New World Screwworm in Multiple Species, Including Sheep, Cattle, Goats, and Swine",
            "item_type": "entry",
            "summary": "added: FDA Issues Emergency Use Authorization for Drug to Prevent New World Screwworm in Multiple Species, Including Sheep, Cattle, Goats, and Swine",
            "after": {
              "title": "FDA Issues Emergency Use Authorization for Drug to Prevent New World Screwworm in Multiple Species, Including Sheep, Cattle, Goats, and Swine",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drug-prevent-new-world-screwworm-multiple-species-including",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drug-prevent-new-world-screwworm-multiple-species-including",
              "author": "FDA",
              "published_at": "2026-08-07T13:00:09Z",
              "updated_at": "2026-08-07T13:00:09Z",
              "summary": "FDA today issued an Emergency Use Authorization (EUA) for CLiK Extra (dicyclanil topical suspension) wound spray for application on or around wounds for the prevention of New World screwworm (NWS) infestations (myiasis).",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 85,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.32"
            },
            {
              "step": "dedupe",
              "version": "0.10.32",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.32",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.32",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drug-prevent-new-world-screwworm-multiple-species-including"
    },
    {
      "id": "341373f2ba931ac13863",
      "title": "FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma",
      "content_text": "The U.S. Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for the treatment of advanced, refractory melanoma.",
      "date_published": "2026-08-06T19:56:59Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "341373f2ba931ac13863",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-29T08:28:52Z",
          "data": {
            "change": "added",
            "label": "FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma",
            "item_type": "entry",
            "summary": "added: FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma",
            "after": {
              "title": "FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma",
              "author": "FDA",
              "published_at": "2026-08-06T19:56:59Z",
              "updated_at": "2026-08-06T19:56:59Z",
              "summary": "The U.S. Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for the treatment of advanced, refractory melanoma.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 85,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.10.32"
            },
            {
              "step": "dedupe",
              "version": "0.10.32",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.10.32",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.10.32",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma"
    },
    {
      "id": "36b858f469d029d37143",
      "title": "Federal Court Enters Consent Decree Against Gold Star Distribution, Inc. Following Persistent Insanitary Warehouse Conditions",
      "content_text": "A U.S. Food and Drug Administration investigation resulted in a federal court order, dated Sept. 21, 2026, stopping a warehouse operator from distributing FDA-regulated products including food, drugs, medical devices, and cosmetics until it fixes its operations to meet federal legal requirements.",
      "date_published": "2026-09-23T19:50:17Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "36b858f469d029d37143",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/federal-court-enters-consent-decree-against-gold-star-distribution-inc-following-persistent",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-26T17:24:30Z",
          "data": {
            "change": "added",
            "label": "Federal Court Enters Consent Decree Against Gold Star Distribution, Inc. Following Persistent Insanitary Warehouse Conditions",
            "item_type": "entry",
            "summary": "added: Federal Court Enters Consent Decree Against Gold Star Distribution, Inc. Following Persistent Insanitary Warehouse Conditions",
            "after": {
              "title": "Federal Court Enters Consent Decree Against Gold Star Distribution, Inc. Following Persistent Insanitary Warehouse Conditions",
              "link": "http://www.fda.gov/news-events/press-announcements/federal-court-enters-consent-decree-against-gold-star-distribution-inc-following-persistent",
              "id": "http://www.fda.gov/news-events/press-announcements/federal-court-enters-consent-decree-against-gold-star-distribution-inc-following-persistent",
              "author": "FDA",
              "published_at": "2026-09-23T19:50:17Z",
              "updated_at": "2026-09-23T19:50:17Z",
              "summary": "A U.S. Food and Drug Administration investigation resulted in a federal court order, dated Sept. 21, 2026, stopping a warehouse operator from distributing FDA-regulated products including food, drugs, medical devices, and cosmetics until it fixes its operations to meet federal legal requirements.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 130,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.9.1"
            },
            {
              "step": "dedupe",
              "version": "0.9.1",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.9.1",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.9.1",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/federal-court-enters-consent-decree-against-gold-star-distribution-inc-following-persistent"
    },
    {
      "id": "2b3428bb22bee286721a",
      "title": "FDA Updates Regulations to Advance Innovative Alternatives to Animal Testing",
      "content_text": "The FDA today issued a direct final rule that updates its regulations to clarify that non-animal methods can be used where appropriate for testing the safety of drugs and biological products intended for human use before they’re tried in humans.",
      "date_published": "2026-09-21T12:58:34Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "2b3428bb22bee286721a",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-updates-regulations-advance-innovative-alternatives-animal-testing",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-26T17:24:30Z",
          "data": {
            "change": "added",
            "label": "FDA Updates Regulations to Advance Innovative Alternatives to Animal Testing",
            "item_type": "entry",
            "summary": "added: FDA Updates Regulations to Advance Innovative Alternatives to Animal Testing",
            "after": {
              "title": "FDA Updates Regulations to Advance Innovative Alternatives to Animal Testing",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-updates-regulations-advance-innovative-alternatives-animal-testing",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-updates-regulations-advance-innovative-alternatives-animal-testing",
              "author": "FDA",
              "published_at": "2026-09-21T12:58:34Z",
              "updated_at": "2026-09-21T12:58:34Z",
              "summary": "The FDA today issued a direct final rule that updates its regulations to clarify that non-animal methods can be used where appropriate for testing the safety of drugs and biological products intended for human use before they’re tried in humans.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 130,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.9.1"
            },
            {
              "step": "dedupe",
              "version": "0.9.1",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.9.1",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.9.1",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-updates-regulations-advance-innovative-alternatives-animal-testing"
    },
    {
      "id": "237155efbd3ff869a34c",
      "title": "FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A",
      "content_text": "The U.S. Food and Drug Administration today approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A.",
      "date_published": "2026-09-17T18:26:43Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "237155efbd3ff869a34c",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-pediatric-patients-sanfilippo-syndrome-type",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-26T17:24:30Z",
          "data": {
            "change": "added",
            "label": "FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A",
            "item_type": "entry",
            "summary": "added: FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A",
            "after": {
              "title": "FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-pediatric-patients-sanfilippo-syndrome-type",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-pediatric-patients-sanfilippo-syndrome-type",
              "author": "FDA",
              "published_at": "2026-09-17T18:26:43Z",
              "updated_at": "2026-09-17T18:26:43Z",
              "summary": "The U.S. Food and Drug Administration today approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 130,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.9.1"
            },
            {
              "step": "dedupe",
              "version": "0.9.1",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.9.1",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.9.1",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-pediatric-patients-sanfilippo-syndrome-type"
    },
    {
      "id": "657a5d0b623029b8b1b6",
      "title": "FDA Grants Accelerated Approval to a New Breast Cancer Treatment",
      "content_text": "The U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting new treatments to patients who need them.",
      "date_published": "2026-09-04T19:38:04Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "657a5d0b623029b8b1b6",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-26T17:24:30Z",
          "data": {
            "change": "added",
            "label": "FDA Grants Accelerated Approval to a New Breast Cancer Treatment",
            "item_type": "entry",
            "summary": "added: FDA Grants Accelerated Approval to a New Breast Cancer Treatment",
            "after": {
              "title": "FDA Grants Accelerated Approval to a New Breast Cancer Treatment",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment",
              "author": "FDA",
              "published_at": "2026-09-04T19:38:04Z",
              "updated_at": "2026-09-04T19:38:04Z",
              "summary": "The U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting new treatments to patients who need them.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 130,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.9.1"
            },
            {
              "step": "dedupe",
              "version": "0.9.1",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.9.1",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.9.1",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment"
    },
    {
      "id": "dc477c4fcae43ad7141e",
      "title": "FDA Approves First Drug to Treat Alexander Disease",
      "content_text": "The U.S. Food and Drug Administration has approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients.",
      "date_published": "2026-09-03T19:48:27Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "dc477c4fcae43ad7141e",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-26T17:24:30Z",
          "data": {
            "change": "added",
            "label": "FDA Approves First Drug to Treat Alexander Disease",
            "item_type": "entry",
            "summary": "added: FDA Approves First Drug to Treat Alexander Disease",
            "after": {
              "title": "FDA Approves First Drug to Treat Alexander Disease",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease",
              "author": "FDA",
              "published_at": "2026-09-03T19:48:27Z",
              "updated_at": "2026-09-03T19:48:27Z",
              "summary": "The U.S. Food and Drug Administration has approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 130,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.9.1"
            },
            {
              "step": "dedupe",
              "version": "0.9.1",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.9.1",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.9.1",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease"
    },
    {
      "id": "67277b3c99352891d965",
      "title": "FDA Issues Emergency Use Authorization for Drugs to Prevent and Treat New World Screwworm in Dogs and Cats",
      "content_text": "The U.S. Food and Drug Administration today issued an Emergency Use Authorization (EUA) for Capstar (nitenpyram) tablets and revised the EUA for Nitenpyram Tablets, the generic version of Capstar",
      "date_published": "2026-09-03T15:01:02Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "67277b3c99352891d965",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drugs-prevent-and-treat-new-world-screwworm-dogs-and-cats",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-26T17:24:30Z",
          "data": {
            "change": "added",
            "label": "FDA Issues Emergency Use Authorization for Drugs to Prevent and Treat New World Screwworm in Dogs and Cats",
            "item_type": "entry",
            "summary": "added: FDA Issues Emergency Use Authorization for Drugs to Prevent and Treat New World Screwworm in Dogs and Cats",
            "after": {
              "title": "FDA Issues Emergency Use Authorization for Drugs to Prevent and Treat New World Screwworm in Dogs and Cats",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drugs-prevent-and-treat-new-world-screwworm-dogs-and-cats",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drugs-prevent-and-treat-new-world-screwworm-dogs-and-cats",
              "author": "FDA",
              "published_at": "2026-09-03T15:01:02Z",
              "updated_at": "2026-09-03T15:01:02Z",
              "summary": "The U.S. Food and Drug Administration today issued an Emergency Use Authorization (EUA) for Capstar (nitenpyram) tablets and revised the EUA for Nitenpyram Tablets, the generic version of Capstar",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 130,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.9.1"
            },
            {
              "step": "dedupe",
              "version": "0.9.1",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.9.1",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.9.1",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drugs-prevent-and-treat-new-world-screwworm-dogs-and-cats"
    },
    {
      "id": "23efa902d6774f033313",
      "title": "FDA Seeks Public Input to Advance Development of Botanical Drug Products",
      "content_text": "The U.S. Food and Drug Administration today announced a request for information (RFI) to gather public input on opportunities to advance the development of botanical drug products.",
      "date_published": "2026-09-03T12:52:49Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "23efa902d6774f033313",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-advance-development-botanical-drug-products",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-26T17:24:30Z",
          "data": {
            "change": "added",
            "label": "FDA Seeks Public Input to Advance Development of Botanical Drug Products",
            "item_type": "entry",
            "summary": "added: FDA Seeks Public Input to Advance Development of Botanical Drug Products",
            "after": {
              "title": "FDA Seeks Public Input to Advance Development of Botanical Drug Products",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-advance-development-botanical-drug-products",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-advance-development-botanical-drug-products",
              "author": "FDA",
              "published_at": "2026-09-03T12:52:49Z",
              "updated_at": "2026-09-03T12:52:49Z",
              "summary": "The U.S. Food and Drug Administration today announced a request for information (RFI) to gather public input on opportunities to advance the development of botanical drug products.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 130,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.9.1"
            },
            {
              "step": "dedupe",
              "version": "0.9.1",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.9.1",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.9.1",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-advance-development-botanical-drug-products"
    },
    {
      "id": "31262e5d4b66ca88442d",
      "title": "FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder",
      "content_text": "The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells.",
      "date_published": "2026-08-28T21:22:41Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "31262e5d4b66ca88442d",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-26T17:24:30Z",
          "data": {
            "change": "added",
            "label": "FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder",
            "item_type": "entry",
            "summary": "added: FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder",
            "after": {
              "title": "FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder",
              "author": "FDA",
              "published_at": "2026-08-28T21:22:41Z",
              "updated_at": "2026-08-28T21:22:41Z",
              "summary": "The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 130,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.9.1"
            },
            {
              "step": "dedupe",
              "version": "0.9.1",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.9.1",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.9.1",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder"
    },
    {
      "id": "79cf79dc092b23fe3bd6",
      "title": "FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults",
      "content_text": "The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets for the treatment of dermatomyositis in adults.",
      "date_published": "2026-08-27T19:11:11Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "79cf79dc092b23fe3bd6",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-drug-indicated-treat-dermatomyositis-adults",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-26T17:24:30Z",
          "data": {
            "change": "added",
            "label": "FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults",
            "item_type": "entry",
            "summary": "added: FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults",
            "after": {
              "title": "FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-drug-indicated-treat-dermatomyositis-adults",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-drug-indicated-treat-dermatomyositis-adults",
              "author": "FDA",
              "published_at": "2026-08-27T19:11:11Z",
              "updated_at": "2026-08-27T19:11:11Z",
              "summary": "The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets for the treatment of dermatomyositis in adults.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 130,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.9.1"
            },
            {
              "step": "dedupe",
              "version": "0.9.1",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.9.1",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.9.1",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-drug-indicated-treat-dermatomyositis-adults"
    },
    {
      "id": "3b06b5752d0a095d212d",
      "title": "FDA Issues Emergency Use Authorization for Generic Drug to Prevent New World Screwworm in Cattle",
      "content_text": "FDA issues Emergency Use Authorization (EUA) for Bimectin (ivermectin) injection for the prevention of New World screwworm (NWS) infestations (myiasis) in cattle when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound.",
      "date_published": "2026-08-27T16:55:38Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "3b06b5752d0a095d212d",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-generic-drug-prevent-new-world-screwworm-cattle",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-26T17:24:30Z",
          "data": {
            "change": "added",
            "label": "FDA Issues Emergency Use Authorization for Generic Drug to Prevent New World Screwworm in Cattle",
            "item_type": "entry",
            "summary": "added: FDA Issues Emergency Use Authorization for Generic Drug to Prevent New World Screwworm in Cattle",
            "after": {
              "title": "FDA Issues Emergency Use Authorization for Generic Drug to Prevent New World Screwworm in Cattle",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-generic-drug-prevent-new-world-screwworm-cattle",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-generic-drug-prevent-new-world-screwworm-cattle",
              "author": "FDA",
              "published_at": "2026-08-27T16:55:38Z",
              "updated_at": "2026-08-27T16:55:38Z",
              "summary": "FDA issues Emergency Use Authorization (EUA) for Bimectin (ivermectin) injection for the prevention of New World screwworm (NWS) infestations (myiasis) in cattle when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 130,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.9.1"
            },
            {
              "step": "dedupe",
              "version": "0.9.1",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.9.1",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.9.1",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-generic-drug-prevent-new-world-screwworm-cattle"
    },
    {
      "id": "79281ba0fec0b4b40272",
      "title": "FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer",
      "content_text": "The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.",
      "date_published": "2026-08-26T14:33:36Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "79281ba0fec0b4b40272",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-26T17:24:30Z",
          "data": {
            "change": "added",
            "label": "FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer",
            "item_type": "entry",
            "summary": "added: FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer",
            "after": {
              "title": "FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer",
              "author": "FDA",
              "published_at": "2026-08-26T14:33:36Z",
              "updated_at": "2026-08-26T14:33:36Z",
              "summary": "The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 130,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.9.1"
            },
            {
              "step": "dedupe",
              "version": "0.9.1",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.9.1",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.9.1",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer"
    },
    {
      "id": "885ebe2ff0c3c2bd7414",
      "title": "FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugar",
      "content_text": "The U.S. Food and Drug Administration today authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 years and older living with diabetes.",
      "date_published": "2026-08-25T18:21:22Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "885ebe2ff0c3c2bd7414",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-authorizes-first-wearable-device-continuously-monitors-both-ketone-levels-and-blood-sugar",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-26T17:24:30Z",
          "data": {
            "change": "added",
            "label": "FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugar",
            "item_type": "entry",
            "summary": "added: FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugar",
            "after": {
              "title": "FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugar",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-authorizes-first-wearable-device-continuously-monitors-both-ketone-levels-and-blood-sugar",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-authorizes-first-wearable-device-continuously-monitors-both-ketone-levels-and-blood-sugar",
              "author": "FDA",
              "published_at": "2026-08-25T18:21:22Z",
              "updated_at": "2026-08-25T18:21:22Z",
              "summary": "The U.S. Food and Drug Administration today authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 years and older living with diabetes.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 130,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.9.1"
            },
            {
              "step": "dedupe",
              "version": "0.9.1",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.9.1",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.9.1",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-authorizes-first-wearable-device-continuously-monitors-both-ketone-levels-and-blood-sugar"
    },
    {
      "id": "7f2475f893153d4a1e80",
      "title": "FDA Authorizes First-Of-Its-Kind Robotic Blood Draw Device",
      "content_text": "The U.S. Food and Drug Administration today authorized the Aletta, the first standalone robotic device that can draw blood from a patient’s arm without hands-on operator intervention.",
      "date_published": "2026-08-19T16:48:13Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "7f2475f893153d4a1e80",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-authorizes-first-its-kind-robotic-blood-draw-device",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-26T17:24:30Z",
          "data": {
            "change": "added",
            "label": "FDA Authorizes First-Of-Its-Kind Robotic Blood Draw Device",
            "item_type": "entry",
            "summary": "added: FDA Authorizes First-Of-Its-Kind Robotic Blood Draw Device",
            "after": {
              "title": "FDA Authorizes First-Of-Its-Kind Robotic Blood Draw Device",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-authorizes-first-its-kind-robotic-blood-draw-device",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-authorizes-first-its-kind-robotic-blood-draw-device",
              "author": "FDA",
              "published_at": "2026-08-19T16:48:13Z",
              "updated_at": "2026-08-19T16:48:13Z",
              "summary": "The U.S. Food and Drug Administration today authorized the Aletta, the first standalone robotic device that can draw blood from a patient’s arm without hands-on operator intervention.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 130,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.9.1"
            },
            {
              "step": "dedupe",
              "version": "0.9.1",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.9.1",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.9.1",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-authorizes-first-its-kind-robotic-blood-draw-device"
    },
    {
      "id": "83edf07b8bd0cea605b4",
      "title": "FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies",
      "content_text": "The U.S. Food and Drug Administration today issued an Emergency Use Authorization (EUA) for Simparica TRIO (sarolaner, moxidectin, and pyrantel chewable tablets) for the treatment of New World screwworm (NWS) infestations (myiasis) in dogs and puppies.",
      "date_published": "2026-08-13T17:02:58Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "83edf07b8bd0cea605b4",
          "source": "rss",
          "type": "change",
          "key": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drug-treat-new-world-screwworm-dogs-and-puppies",
          "source_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
          "timestamp": null,
          "observed_at": "2026-09-26T17:24:30Z",
          "data": {
            "change": "added",
            "label": "FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies",
            "item_type": "entry",
            "summary": "added: FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies",
            "after": {
              "title": "FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies",
              "link": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drug-treat-new-world-screwworm-dogs-and-puppies",
              "id": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drug-treat-new-world-screwworm-dogs-and-puppies",
              "author": "FDA",
              "published_at": "2026-08-13T17:02:58Z",
              "updated_at": "2026-08-13T17:02:58Z",
              "summary": "The U.S. Food and Drug Administration today issued an Emergency Use Authorization (EUA) for Simparica TRIO (sarolaner, moxidectin, and pyrantel chewable tablets) for the treatment of New World screwworm (NWS) infestations (myiasis) in dogs and puppies.",
              "categories": [],
              "feed": {
                "title": "FDA Press Releases RSS Feed",
                "url": "http://www.fda.gov/",
                "feed_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml"
              }
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://www.fda.gov/about-fda/contact-fda/stay-informed/rss-feeds/press-releases/rss.xml",
            "elapsed_ms": 130,
            "not_modified": false,
            "method": "rss20"
          },
          "provenance": [
            {
              "step": "rss",
              "version": "0.9.1"
            },
            {
              "step": "dedupe",
              "version": "0.9.1",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "sort",
              "version": "0.9.1",
              "args": {
                "by": [
                  "published_at"
                ],
                "reverse": true
              }
            },
            {
              "step": "diff",
              "version": "0.9.1",
              "args": {
                "namespace": "fda-news",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "http://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-drug-treat-new-world-screwworm-dogs-and-puppies"
    }
  ]
}
